By Dr. Luke Fletcher Willamette Valley Cancer Institute & Research Center Low-risk MDS had many exciting updates, starting with the COMMANDS trial. This study is an open-label randomized phase 3 trial
On August 28, 2023, the U.S. Food and Drug Administration approved luspatercept-aamt (Reblozyl) for the treatment of anemia in adult patients with very low- to intermediate-risk myelodysplastic syndromes (MDS) without prior erythropoiesis-stimulating agent (ESA) use,
More
By Dr. Luke Fletcher Willamette Valley Cancer Institute & Research Center Hodgkin’s lymphoma (HL) has had an exciting and interesting recent history with the introduction of brentuximab (BV) +AVD (Adriamycin, vinblastine,
More
Imetelstat in low-risk MDS for transfusion independence By Dr. Luke Fletcher Willamette Valley Cancer Institute & Research Center ASCO presented an anticipated update to imetelstat in MDS. In the phase
More
By Dr. Luke Fletcher Willamette Valley Cancer Institute & Research Center Low-risk MDS had many exciting updates, starting with the COMMANDS trial. This study is an open-label randomized phase 3 trial
More
By Dr. Chepsy Philip Believer’s Church Medical College Hospital Myeloproliferative – Chronic Myelomonocytic Leukemia (MP-CMML), a subset in the rare patient population of CMML, is associated with poor prognosis. Hydroxyurea (HY)
More
By Dr. Aditi Sharma of Barbara Ann Karmanos Cancer Institute & Dr. Abhishek Mangaonkar of Mayo Clinic In the longer-term follow-up of the phase III ASCEMBL trial published in Leukemia, Andreas
More
The Binaytara Foundation organized three in-person oncology conferences in October 2021. The 2021 Updates in Hematologic Malignancies and the 2021 Precision Oncology Summit were held in Salt Lake City, Utah on October
More